Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP ...

Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder ...

Jonas Salk quietly built the polio vaccine through rigorous, methodical work in Pittsburgh: treating patients, refinin ...

Researchers have made a major advance in quantum computing with a new device that is nearly 100 times smaller than the ...

Synaptic plasticity—the brain's ability to modify the connections between neurons to support learning—is one of the neural ...

Doing more with less in electronics often means improving power density. One of the new areas garnering attention involves applying a variety of advanced modulation techniques, including PWM and space ...

EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedema Phase IIb trial to ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter, randomized, ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today ...

Phases 1-3 of the Oasis de Atacama project in Chile will have a combined capacity of 451MW for solar PV and 2.5GWh for BESS. Image: Grenergy. Spanish independent power producer (IPP) Grenergy has sold ...